How has recent evidence and the ESC 2023 guidelines changed management of heart failure?
Featuring
Professor Christiane Angermann | Germany
Professor Ricardo Carvalho | Portugal
Related content
Document ID: PC-ASK-100580
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Theresa McDonagh (United Kingdom)
What's new for the treatment of chronic heart failure from the ESC 2023 guidelines?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Summary)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)